FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2124967121> ?p ?o ?g. }

• W2124967121 endingPage "786" @default.
• W2124967121 startingPage "777" @default.
• W2124967121 abstract "The results of FASTACT, a randomised, placebo-controlled, phase 2 study, showed that intercalated chemotherapy and erlotinib significantly prolonged progression-free survival (PFS) in patients with advanced non-small-cell lung cancer. We undertook FASTACT-2, a phase 3 study in a similar patient population.In this phase 3 trial, patients with untreated stage IIIB/IV non-small-cell lung cancer were randomly assigned in a 1:1 ratio by use of an interactive internet response system with minimisation algorithm (stratified by disease stage, tumour histology, smoking status, and chemotherapy regimen) to receive six cycles of gemcitabine (1250 mg/m(2) on days 1 and 8, intravenously) plus platinum (carboplatin 5 × area under the curve or cisplatin 75 mg/m(2) on day 1, intravenously) with intercalated erlotinib (150 mg/day on days 15-28, orally; chemotherapy plus erlotinib) or placebo orally (chemotherapy plus placebo) every 4 weeks. With the exception of an independent group responsible for monitoring data and safety monitoring board, everyone outside the interactive internet response system company was masked to treatment allocation. Patients continued to receive erlotinib or placebo until progression or unacceptable toxicity or death, and all patients in the placebo group were offered second-line erlotinib at the time of progression. The primary endpoint was PFS in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT00883779.From April 29, 2009, to Sept 9, 2010, 451 patients were randomly assigned to chemotherapy plus erlotinib (n=226) or chemotherapy plus placebo (n=225). PFS was significantly prolonged with chemotherapy plus erlotinib versus chemotherapy plus placebo (median PFS 7·6 months [95% CI 7·2-8·3], vs 6·0 months [5·6-7·1], hazard ratio [HR] 0·57 [0·47-0·69]; p<0·0001). Median overall survival for patients in the chemotherapy plus erlotinib and chemotherapy plus placebo groups was 18·3 months (16·3-20·8) and 15·2 months (12·7-17·5), respectively (HR 0·79 [0·64-0·99]; p=0·0420). Treatment benefit was noted only in patients with an activating EGFR gene mutation (median PFS 16·8 months [12·9-20·4] vs 6·9 months [5·3-7·6], HR 0·25 [0·16-0·39]; p<0·0001; median overall survival 31·4 months [22·2-undefined], vs 20·6 months [14·2-26·9], HR 0·48 [0·27-0·84]; p=0·0092). Serious adverse events were reported by 76 (34%) of 222 patients in the chemotherapy plus placebo group and 69 (31%) of 226 in the chemotherapy plus erlotinib group. The most common grade 3 or greater adverse events were neutropenia (65 [29%] patients and 55 [25%], respectively), thrombocytopenia (32 [14%] and 31 [14%], respectively), and anaemia (26 [12%] and 21 [9%], respectively).Intercalated chemotherapy and erlotinib is a viable first-line option for patients with non-small-cell lung cancer with EGFR mutation-positive disease or selected patients with unknown EGFR mutation status.F Hoffmann-La Roche." @default.
• W2124967121 created "2016-06-24" @default.
• W2124967121 creator A5003999850 @default.
• W2124967121 creator A5006820907 @default.
• W2124967121 creator A5008578055 @default.
• W2124967121 creator A5010034475 @default.
• W2124967121 creator A5015023254 @default.
• W2124967121 creator A5016245266 @default.
• W2124967121 creator A5016616468 @default.
• W2124967121 creator A5021570053 @default.
• W2124967121 creator A5024451482 @default.
• W2124967121 creator A5027378939 @default.
• W2124967121 creator A5027396582 @default.
• W2124967121 creator A5038306289 @default.
• W2124967121 creator A5045553246 @default.
• W2124967121 creator A5047727465 @default.
• W2124967121 creator A5048034942 @default.
• W2124967121 creator A5055974749 @default.
• W2124967121 creator A5056956175 @default.
• W2124967121 creator A5061940066 @default.
• W2124967121 creator A5065884417 @default.
• W2124967121 creator A5066716873 @default.
• W2124967121 creator A5066717752 @default.
• W2124967121 creator A5070808098 @default.
• W2124967121 creator A5071569707 @default.
• W2124967121 creator A5072522693 @default.
• W2124967121 creator A5074050721 @default.
• W2124967121 creator A5075839357 @default.
• W2124967121 creator A5075877965 @default.
• W2124967121 creator A5082772889 @default.
• W2124967121 creator A5086194746 @default.
• W2124967121 creator A5087860798 @default.
• W2124967121 creator A5089573339 @default.
• W2124967121 date "2013-07-01" @default.
• W2124967121 modified "2023-09-23" @default.
• W2124967121 title "Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial" @default.
• W2124967121 cites W1972304790 @default.
• W2124967121 cites W1984146948 @default.
• W2124967121 cites W2004484157 @default.
• W2124967121 cites W2018798914 @default.
• W2124967121 cites W2043696829 @default.
• W2124967121 cites W2097779924 @default.
• W2124967121 cites W2100912832 @default.
• W2124967121 cites W2110835998 @default.
• W2124967121 cites W2111662961 @default.
• W2124967121 cites W2113491100 @default.
• W2124967121 cites W2116827288 @default.
• W2124967121 cites W2118320591 @default.
• W2124967121 cites W2129360604 @default.
• W2124967121 cites W2131795655 @default.
• W2124967121 cites W2132157071 @default.
• W2124967121 cites W2134964659 @default.
• W2124967121 cites W2135192471 @default.
• W2124967121 cites W2148255146 @default.
• W2124967121 cites W2148398719 @default.
• W2124967121 cites W2150575159 @default.
• W2124967121 cites W2154662831 @default.
• W2124967121 cites W2160982674 @default.
• W2124967121 cites W2161821474 @default.
• W2124967121 cites W2162724777 @default.
• W2124967121 cites W2165771694 @default.
• W2124967121 cites W2166084034 @default.
• W2124967121 cites W2999318345 @default.
• W2124967121 doi "https://doi.org/10.1016/s1470-2045(13)70254-7" @default.
• W2124967121 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23782814" @default.
• W2124967121 hasPublicationYear "2013" @default.
• W2124967121 type Work @default.
• W2124967121 sameAs 2124967121 @default.
• W2124967121 citedByCount "267" @default.
• W2124967121 countsByYear W21249671212013 @default.
• W2124967121 countsByYear W21249671212014 @default.
• W2124967121 countsByYear W21249671212015 @default.
• W2124967121 countsByYear W21249671212016 @default.
• W2124967121 countsByYear W21249671212017 @default.
• W2124967121 countsByYear W21249671212018 @default.
• W2124967121 countsByYear W21249671212019 @default.
• W2124967121 countsByYear W21249671212020 @default.
• W2124967121 countsByYear W21249671212021 @default.
• W2124967121 countsByYear W21249671212022 @default.
• W2124967121 countsByYear W21249671212023 @default.
• W2124967121 crossrefType "journal-article" @default.
• W2124967121 hasAuthorship W2124967121A5003999850 @default.
• W2124967121 hasAuthorship W2124967121A5006820907 @default.
• W2124967121 hasAuthorship W2124967121A5008578055 @default.
• W2124967121 hasAuthorship W2124967121A5010034475 @default.
• W2124967121 hasAuthorship W2124967121A5015023254 @default.
• W2124967121 hasAuthorship W2124967121A5016245266 @default.
• W2124967121 hasAuthorship W2124967121A5016616468 @default.
• W2124967121 hasAuthorship W2124967121A5021570053 @default.
• W2124967121 hasAuthorship W2124967121A5024451482 @default.
• W2124967121 hasAuthorship W2124967121A5027378939 @default.
• W2124967121 hasAuthorship W2124967121A5027396582 @default.
• W2124967121 hasAuthorship W2124967121A5038306289 @default.
• W2124967121 hasAuthorship W2124967121A5045553246 @default.
• W2124967121 hasAuthorship W2124967121A5047727465 @default.
• W2124967121 hasAuthorship W2124967121A5048034942 @default.
• W2124967121 hasAuthorship W2124967121A5055974749 @default.
• W2124967121 hasAuthorship W2124967121A5056956175 @default.

• next